MINNEAPOLIS, Dec. 8, 2010 /PRNewswire-FirstCall/ -- Uroplasty, Inc. (Nasdaq: UPI), a medical device company that develops, manufactures and markets innovative proprietary products to treat voiding dysfunctions, today announced the appointment of Mr. Robert (Rob) Kill to its Board of Directors. Mr. Kill's appointment increases the membership on the Board to seven.
Mr. Kill (46) is the President, CEO and a Board member of Virtual Radiologic Corporation, a Minneapolis-based, high growth provider of teleradiology and technology solutions to radiology practices and hospitals throughout the United States. Prior to joining Virtual Radiologic, Mr. Kill served as President of the Physicians Systems business at Misys Healthcare, a developer of healthcare software systems. Earlier, he spent 10 years with Baxter Healthcare, where he held senior leadership positions in operations, marketing and sales. He holds a B.A. in Economics from the University of Notre Dame.
"We are very pleased to have Rob join our Board at this key time at Uroplasty," said Patrick Maxwell, Chairman of the Board. "His 19 years of experience with growing medical products and service companies will be extremely valuable to us as we execute our strategy to drive revenue growth and enhance valuation for our shareholders."
"I am excited to join Uroplasty's Board as the Company re-launches its Urgent PC Neuromodulation System in the U.S. for the treatment of overactive bladder," said Mr. Kill. "I believe that my experience in a high growth environment will be of value to Uroplasty's Board and shareholders during this pivotal time in the Company's development."
David Kaysen, President and CEO of Uroplasty said, "Rob brought Virtual Radiologic public, growing it several fold in four years, and then sold the company in a private transaction. As we roll out the re